Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Primary Myelofibrosis 3Myeloproliferative Disorders 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2Thrombocytosis 1Solid Tumors 1Polycythemia Vera 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inhibition, Psychological 1Head and Neck Neoplasms 1Graft vs Host Disease 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1B-cell Malignancies 1B-Cell Malignancies 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Azacitidine 14venetoclax 10AP 1903 reagent 7Rituximab 6Dexamethasone 6Itraconazole 5Cytarabine 5Bortezomib 5fludarabine 4fedratinib 4belinostat 4Nivolumab 4Lenalidomide 4Imatinib Mesylate 4Daunorubicin 4ARQ531 4pomalidomide 3ibrutinib 3daratumumab 3cc-486 3angiotensin I (1-7) 3Standard of Care 3GSK2110183 3Cyclophosphamide 3zanubrutinib 2tosedostat 2tazemetostat 2tanespimycin 2talquetamab 2tafasitamab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Neoplasms × INCB039110 × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Incyte Corporation

Phase 2 Withdrawn
Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡